A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma

• Research surrounding treatment of leiomyosarcoma (LMS) treatment remains sparse. • Pembrolizumab/lenvatinib has been reported as a therapy for endometrial cancer, though not yet as therapy for LMS. • This report demonstrates disease regression after use of pembrolizumab and lenvatinib in a patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Naaman, Lee, Sarah S., Salame, Ghadir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932649/
https://www.ncbi.nlm.nih.gov/pubmed/36818196
http://dx.doi.org/10.1016/j.gore.2023.101145
Descripción
Sumario:• Research surrounding treatment of leiomyosarcoma (LMS) treatment remains sparse. • Pembrolizumab/lenvatinib has been reported as a therapy for endometrial cancer, though not yet as therapy for LMS. • This report demonstrates disease regression after use of pembrolizumab and lenvatinib in a patient with recurrent LMS.

Ejemplares similares